They withheld medtone for a reason. Besides being very embarrassing. Treat to target with medtone and all the " lost" insulin which likely works as along acting insulin absorbed through tissue could be interesting.
MedTone was not the subject of the trial! The FDA has all the data they need and more on the MedTone from prior trials. It passed muster, otherwise FDA would not have resurrected it and submitted 171 patients to its perils.. It was there only to compare to the Dreamboat Gen2. They are the same company says, no appreciable difference in results of two arms, comparable data... Summer Street is wrong, dead wrong, and intellectually dishonest. MNKD withheld no data. It will be in published data later in year. Should they not bother to submit data and file NDA?
And what is all your clone talk, jibbajabbaflibbaflabba. I bought at 1.90 and sold at 6.5, 7.06 and 8.06. 90,000 shares. I wanted to believe but now I have questions.. If you guys are so well informed then you should have seen a 2 + billion market cap as excessive. I will get back in when these questions are answered. Summer Street has valid questions.
New issues can arise from clinical trials, if something unexpected pops up. They won't overlook it just because of predetermined protocol. They created an unexpected issue last time they answered a CRL , and that is in Matt's words not mine.